New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer

2001 ◽  
Vol 28 (2 Suppl 4) ◽  
pp. 27-29 ◽  
Author(s):  
David S. Ettinger
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
New Drugs ◽  
Small Cell Lung ◽  
Extensive Disease

scholarly journals History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 998
Author(s):  
Chiara Lazzari ◽  
Aurora Mirabile ◽  
Alessandra Bulotta ◽  
Maria Grazia Viganó ◽  
Francesca Rita Ogliari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Time ◽  
Small Cell ◽  
Review Of The Literature ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
History Of ◽  
Line Standard

Several trials have tried for decades to improve the outcome of extensive disease small cell lung cancer (ED-SCLC) through attempts to modify the standard treatments. Nevertheless, platinum/etoposide combination and topotecan have remained respectively the first and the second line standard treatments for the last 40 years. With the advent of immunotherapy, this scenario has finally changed. Our review aims to provide an overview of the primary studies on the actual therapeutic strategies available for ED-SCLC patients, and to highlight emerging evidence supporting the use of immunotherapy in SCLC patients.

scholarly journals Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer

Biomedicines ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 48
Author(s):  
Patricia Mondelo-Macía ◽  
Jorge García-González ◽  
Luis León-Mateos ◽  
Adrián Castillo-García ◽  
Rafael López-López ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Liquid Biopsy ◽  
Small Cell ◽  
New Drugs ◽  
Current Status ◽  
Small Cell Lung ◽  
Tumor Biopsy ◽  
Future Utility

Approximately 19% of all cancer-related deaths are due to lung cancer, which is the leading cause of mortality worldwide. Small cell lung cancer (SCLC) affects approximately 15% of patients diagnosed with lung cancer. SCLC is characterized by aggressiveness; the majority of SCLC patients present with metastatic disease, and less than 5% of patients are alive at 5 years. The gold standard of SCLC treatment is platinum and etoposide-based chemotherapy; however, its effects are short. In recent years, treatment for SCLC has changed; new drugs have been approved, and new biomarkers are needed for treatment selection. Liquid biopsy is a non-invasive, rapid, repeated and alternative tool to the traditional tumor biopsy that could allow the most personalized medicine into the management of SCLC patients. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) are the most commonly used liquid biopsy biomarkers. Some studies have reported the prognostic factors of CTCs and cfDNA in SCLC patients, independent of the stage. In this review, we summarize the recent SCLC studies of CTCs, cfDNA and other liquid biopsy biomarkers, and we discuss the future utility of liquid biopsy in the clinical management of SCLC.

scholarly journals P30-3 Clinical experience of tumour lysis syndrome in patients with extensive disease small cell lung cancer

2021 ◽  
Vol 32 ◽  
pp. S348
Author(s):  
Megumi Kawamoto ◽  
Yoshiyuki Sano ◽  
Yoshitaka Zenke ◽  
Kenji Kawasumi ◽  
Hiroki Izumi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Experience ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Tumour Lysis Syndrome ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
Tumour Lysis

scholarly journals Extensive Disease Small Cell Lung Cancer Dose-Response Relationships: Implications for Resistance Mechanisms

2010 ◽  
Vol 5 (11) ◽  
pp. 1826-1834 ◽  
Author(s):  
David J. Stewart ◽  
Constance Johnson ◽  
Adriana Lopez ◽  
Bonnie Glisson ◽  
Jay M. Rhee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dose Response ◽  
Resistance Mechanisms ◽  
Small Cell ◽  
Small Cell Lung ◽  
Extensive Disease

scholarly journals Combination of bevacizumab and dual immunotherapy for extensive-disease small-cell lung cancer: a case report

Immunotherapy ◽  
2021 ◽  
Author(s):  
Lei Song ◽  
Rengui Zhou ◽  
Xiangyong Li ◽  
Dejian Pan
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Survival Time ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
The Third ◽  
Third Line

Small-cell lung cancer (SCLC) is sensitive to chemoradiotherapy but remains to have a poor prognosis. In the immunotherapy era, chemotherapy combined with PD-L1 inhibitors has become a new first-line treatment option for advanced SCLC. The CheckMate 032 study combined a PD-1 blockade and a CTLA-4 inhibitor and found that this dual immunotherapy might be a positive treatment choice for SCLC. In our case, the patient with advanced SCLC received bevacizumab combined with dual immunotherapy over the third line with more than 12 months survival time. The overall survival time was 21.5 months from the start of the third-line treatment and 39 months from the time of extensive-disease SCLC diagnosis. The combination of a VEGF blockade and a dual immunotherapy in SCLC resulted in synergistic treatment effects. Therefore, bevacizumab might be a better adjuvant, either combined with chemotherapy or dual immunotherapy, for patients with persistent disease progression after undergoing immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document